Abrahão Elias Hallack Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abrahão Elias Hallack Neto has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Nelson Hamerschlak
Hospital Israelita Albert Einstein, Bone Marrow Transplantation Unit, Sao Paulo, Brazil
10 shared publications - Afonso Celso Vigorito
Universidade Estadual de Campinas – Campinas (SP), Brazil
8 shared publications - Fernando Barroso Duarte
Hospital Universitário Walter Cantídio – Fortaleza (CE), Brazil
8 shared publications - Maria Claudia Rodrigues Moreira
Complexo Hospital de Niterói, RJ, Brazil
8 shared publications - Rodolfo Daniel de Almeida Soares
Natal Hospital Center – Natal (RN), Brazil
8 shared publications - Angelo Atalla
Hospital Monte Sinai, Juiz de Fora, MG
7 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Journal of Surgical Oncology
Brazilian Society of Surgical Oncology Guideline for Bloodless Surgery. (Part 2: Intraoperative Strategies)
Introduction: The Brazilian Society of Surgical Oncology (SBCO) developed evidence‐informed consensus recommendations for intraoperative blood conservation and the rational use of blood components in surgical patients. Methods: Between June and December 2024, a multidisciplinary panel of 40 experts developed 48 clinical questions covering three perioperative phases: preoperative, intraoperative, and postoperative care. This second article of the series addresses 16 questions related to intraoperative blood conservation. Expert working groups conducted structured literature reviews and drafted preliminary recommendations, which were subsequently reviewed by the project coordinators and submitted to an online consensus vote. Because high‐quality oncology‐specific evidence was limited for some questions, evidence from other surgical populations was considered when clinically applicable, with indirectness reflected in the wording and grading of the recommendations. An adapted evidence‐classification system was used to determine the level of evidence and grade of recommendation. Conclusion: Intraoperative blood conservation requires an individualized, multimodal, and multidisciplinary approach. The selection of anesthetic, pharmacological, surgical, and blood‐conservation interventions should consider the quality and directness of the available evidence, patient characteristics, surgical complexity, expected blood loss, and patient preferences.
- 15 November 2026
- Published by Wiley in Journal of Surgical Oncology
Open AccessBrazilian Society of Surgical Oncology Guideline for Bloodless Surgery. (Part 2: Intraoperative Strategies)
Introduction: The Brazilian Society of Surgical Oncology (SBCO) developed evidence‐informed consensus recommendations for intraoperative blood conservation and the rational use of blood components in surgical patients. Methods: Between June and December 2024, a multidisciplinary panel of 40 experts developed 48 clinical questions covering three perioperative phases: preoperative, intraoperative, and postoperative care. This second article of the series addresses 16 questions related to intraoperative blood conservation. Expert working groups conducted structured literature reviews and drafted preliminary recommendations, which were subsequently reviewed by the project coordinators and submitted to an online consensus vote. Because high‐quality oncology‐specific evidence was limited for some questions, evidence from other surgical populations was considered when clinically applicable, with indirectness reflected in the wording and grading of the recommendations. An adapted evidence‐classification system was used to determine the level of evidence and grade of recommendation. Conclusion: Intraoperative blood conservation requires an individualized, multimodal, and multidisciplinary approach. The selection of anesthetic, pharmacological, surgical, and blood‐conservation interventions should consider the quality and directness of the available evidence, patient characteristics, surgical complexity, expected blood loss, and patient preferences.
- Open Access
- 27 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2321-2325
Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma
- 27 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2321-2325
Open AccessReal‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma
- Open Access
- 29 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1406.e1-1406.e5
Comparison of Carmustine-, Lomustine-, and Nitrosourea-Free Conditioning Regimens for Autologous HCT (Auto-HCT) in Lymphoma: Results From the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR)
- 29 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1406.e1-1406.e5
Open AccessComparison of Carmustine-, Lomustine-, and Nitrosourea-Free Conditioning Regimens for Autologous HCT (Auto-HCT) in Lymphoma: Results From the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR)
- Open Access
- 20 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 907.e1-907.e11
Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hypoplastic Myelodysplastic Syndrome: A Latin American Multicenter Analysis
- 20 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 907.e1-907.e11
Open AccessOutcomes of Allogeneic Hematopoietic Cell Transplantation for Hypoplastic Myelodysplastic Syndrome: A Latin American Multicenter Analysis
- Open Access
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Effectiveness of dose-intensified regimens in early progressed follicular lymphoma before autologous stem cell transplantation: A systematic review and meta-analysis
Introduction: Despite the substantial advances in the management of follicular lymphoma, approximately 20% of these patients have worse outcomes, experiencing early progression of the disease after induction therapy. Autologous stem cell transplantation may improve survival in this context. Little is known about the optimal salvage regimen. Purpose: To evaluate the effectiveness of dose-intensified versus standard-dose salvage regimen in adult patients diagnosed with early progressed follicular lymphoma before autologous stem cell transplantation. Methods: This systematic review and meta-analysis adhere to the Joanna Briggs Institute methodology for systematic reviews of effectiveness and Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We searched Medline, Embase, Scopus, Web of Science, Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane Library databases and gray literature for eligible studies. Results: In total, 494 studies were considered for title and abstract screening. After full review, two studies were eligible for data extraction. Both studies were single arm retrospective cohorts with patients receiving dose-intensified regimens as salvage regimen. Due to missing values, we could not perform a pooled analysis of time-dependent outcomes. We performed a proportional meta-analysis for overall response rate. An odds ratio of 0.93 (95% confidence interval 0.81–0.97) was demonstrated using the random-effects model. Data synthesis showed a low degree of heterogeneity. Conclusion: Using the GRADE approach, our data suggested that dose-intensified salvage regimens are a feasible option with low certainty of evidence, due to serious risk of bias and serious indirectness.
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Open AccessEffectiveness of dose-intensified regimens in early progressed follicular lymphoma before autologous stem cell transplantation: A systematic review and meta-analysis
Introduction: Despite the substantial advances in the management of follicular lymphoma, approximately 20% of these patients have worse outcomes, experiencing early progression of the disease after induction therapy. Autologous stem cell transplantation may improve survival in this context. Little is known about the optimal salvage regimen. Purpose: To evaluate the effectiveness of dose-intensified versus standard-dose salvage regimen in adult patients diagnosed with early progressed follicular lymphoma before autologous stem cell transplantation. Methods: This systematic review and meta-analysis adhere to the Joanna Briggs Institute methodology for systematic reviews of effectiveness and Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We searched Medline, Embase, Scopus, Web of Science, Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane Library databases and gray literature for eligible studies. Results: In total, 494 studies were considered for title and abstract screening. After full review, two studies were eligible for data extraction. Both studies were single arm retrospective cohorts with patients receiving dose-intensified regimens as salvage regimen. Due to missing values, we could not perform a pooled analysis of time-dependent outcomes. We performed a proportional meta-analysis for overall response rate. An odds ratio of 0.93 (95% confidence interval 0.81–0.97) was demonstrated using the random-effects model. Data synthesis showed a low degree of heterogeneity. Conclusion: Using the GRADE approach, our data suggested that dose-intensified salvage regimens are a feasible option with low certainty of evidence, due to serious risk of bias and serious indirectness.
- Open Access
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Current activity trends and outcomes of hematopoietic cell transplantation: A 2026 report from the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the CIBMTR & SBTMO
The development of the Brazilian Registry of Hematopoietic Cell Transplantation (Registro Brasileiro de Transplantes de Células Hematopoieticas), in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR), continues to provide a comprehensive assessment of hematopoietic cell transplantation (HCT) activity and outcomes in Brazil. In this study, we report an updated analysis of national transplant activity. Brazilian transplant centers report their data to the CIBMTR using the FormsNet3 platform, and data are returned to the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea) through the Data Back to Centers (DBtC) tool. Data from patients who underwent HCT from 2015 to 2025 in Brazilian centers were extracted from the CIBMTR. Descriptive analyses were performed using patient-, disease-, and transplant-related variables, and overall survival was estimated using the Kaplan–Meier method. A total of 15,586 HCTs were included (7,507 autologous and 8,079 allogeneic). For survival analyses, 9,150 patients who underwent a first HCT from 2015 to 2023 were analyzed, with a median follow-up of 35 months. The number of reporting centers increased over time, reaching 51 centers during the study period. Acute leukemias remained the most common indication for allogeneic HCT, while multiple myeloma and lymphomas predominated in autologous HCT. In recent years, mismatched related donors have accounted for the largest proportion of allogeneic transplants. Bone marrow was the main graft source in pediatric patients, whereas peripheral blood predominated in adults. Infections were the most frequent cause of death within the first 100 days after HCT, while primary disease was the leading cause beyond 100 days. Survival patterns varied according to disease characteristics and transplantrelated factors, with lower survival estimates observed in patients transplanted with advanced disease stages. Comparisons with the United States Summary Slides suggest both similarities and differences in transplant activity and outcomes, which should be interpreted with caution given variations in data structure, patient characteristics, and risk stratification.
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Open AccessCurrent activity trends and outcomes of hematopoietic cell transplantation: A 2026 report from the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the CIBMTR & SBTMO
The development of the Brazilian Registry of Hematopoietic Cell Transplantation (Registro Brasileiro de Transplantes de Células Hematopoieticas), in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR), continues to provide a comprehensive assessment of hematopoietic cell transplantation (HCT) activity and outcomes in Brazil. In this study, we report an updated analysis of national transplant activity. Brazilian transplant centers report their data to the CIBMTR using the FormsNet3 platform, and data are returned to the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea) through the Data Back to Centers (DBtC) tool. Data from patients who underwent HCT from 2015 to 2025 in Brazilian centers were extracted from the CIBMTR. Descriptive analyses were performed using patient-, disease-, and transplant-related variables, and overall survival was estimated using the Kaplan–Meier method. A total of 15,586 HCTs were included (7,507 autologous and 8,079 allogeneic). For survival analyses, 9,150 patients who underwent a first HCT from 2015 to 2023 were analyzed, with a median follow-up of 35 months. The number of reporting centers increased over time, reaching 51 centers during the study period. Acute leukemias remained the most common indication for allogeneic HCT, while multiple myeloma and lymphomas predominated in autologous HCT. In recent years, mismatched related donors have accounted for the largest proportion of allogeneic transplants. Bone marrow was the main graft source in pediatric patients, whereas peripheral blood predominated in adults. Infections were the most frequent cause of death within the first 100 days after HCT, while primary disease was the leading cause beyond 100 days. Survival patterns varied according to disease characteristics and transplantrelated factors, with lower survival estimates observed in patients transplanted with advanced disease stages. Comparisons with the United States Summary Slides suggest both similarities and differences in transplant activity and outcomes, which should be interpreted with caution given variations in data structure, patient characteristics, and risk stratification.
- Open Access
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Hematopoietic cell transplantation outcomes in public centers in Brazil: analysis of the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy, 2012–2024
This study provides a national overview of hematopoietic cell transplantation (HCT) outcomes in the Brazil’s public healthcare network, using data consolidated in the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy (RBTCH-TC). A total of 5,923 first HCTs performed between 2012 and 2024 across 19 public centers were analyzed. Median follow-up among survivors reached 24.5 months, reflecting recent improvements in follow-up completeness and data reliability within the registry. Overall survival, relapse, and non-relapse mortality (NRM) rates were generally consistent with international benchmarks, despite the resource limitations characteristic of a publicly funded system. NRM was concentrated in the first year after allogeneic HCT, whereas relapse remained the predominant cause of late mortality across both autologous and allogeneic procedures. Acute graft versus-host disease (GVHD) was more frequent among recipients of mismatched related and unrelated donors, while chronic GVHD occurred more often in matched related donor transplants. These findings highlight the complexity of transplant care in the public setting and underscore the importance of standardized data collection, integration across centers, and long-term surveillance to support continuous quality improvement. Strengthening national collaborative initiatives such as the RBTCH-TC remains essential for guiding evidence-based strategies and improving patient outcomes throughout Brazil’s public transplant network.
- 8 January 2026
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 7 (1)
Open AccessHematopoietic cell transplantation outcomes in public centers in Brazil: analysis of the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy, 2012–2024
This study provides a national overview of hematopoietic cell transplantation (HCT) outcomes in the Brazil’s public healthcare network, using data consolidated in the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy (RBTCH-TC). A total of 5,923 first HCTs performed between 2012 and 2024 across 19 public centers were analyzed. Median follow-up among survivors reached 24.5 months, reflecting recent improvements in follow-up completeness and data reliability within the registry. Overall survival, relapse, and non-relapse mortality (NRM) rates were generally consistent with international benchmarks, despite the resource limitations characteristic of a publicly funded system. NRM was concentrated in the first year after allogeneic HCT, whereas relapse remained the predominant cause of late mortality across both autologous and allogeneic procedures. Acute graft versus-host disease (GVHD) was more frequent among recipients of mismatched related and unrelated donors, while chronic GVHD occurred more often in matched related donor transplants. These findings highlight the complexity of transplant care in the public setting and underscore the importance of standardized data collection, integration across centers, and long-term surveillance to support continuous quality improvement. Strengthening national collaborative initiatives such as the RBTCH-TC remains essential for guiding evidence-based strategies and improving patient outcomes throughout Brazil’s public transplant network.
- Open Access
- 26 June 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 349-357
Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry
This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo‐HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988–2023). Of the 441 patients, 70 (16%) were ≥ 65 years (median age 68 ± 3.7). At 5 years, overall survival (OS) was 49.3% in patients ≥ 65 vs. 56.7% in those < 65 (p = 0.49), and progression‐free survival (PFS) was 48.4% vs. 56.2% (p = 0.40). The cumulative incidence of relapse was 13.6%, and non‐relapse mortality (NRM) 33.8%. After propensity score matching, no significant differences were observed between the age groups in OS (HR = 1.16; 95% CI: 0.76–1.77; p = 0.488), NRM (HR = 1.03; 95% CI: 0.64–1.67; p = 0.90) or PFS (HR = 1.20; 95% CI: 0.779–1.83; p = 0.40). PFS in patients ≥ 65 years was associated with high‐risk IPSS‐R stratification (p = 0.0056). The age group ≥ 65 years conferred higher risk of relapse compared to patients aged < 65 years (HR = 2.77; 95% CI: 1.07–7.15; p = 0.035). In patients ≥ 65 years, prevalence risk was associated to male sex, reduced‐intensity conditioning, mobilized blood cells, and prior treatment, while in those < 65 years, to complications and chronic GVHD (p < 0.05). HCT is feasible in elderly patients. However, age may influence disease progression in very high‐risk elderly patients and risk of relapse after transplantation.
- 26 June 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 349-357
Open AccessOutcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry
This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo‐HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988–2023). Of the 441 patients, 70 (16%) were ≥ 65 years (median age 68 ± 3.7). At 5 years, overall survival (OS) was 49.3% in patients ≥ 65 vs. 56.7% in those < 65 (p = 0.49), and progression‐free survival (PFS) was 48.4% vs. 56.2% (p = 0.40). The cumulative incidence of relapse was 13.6%, and non‐relapse mortality (NRM) 33.8%. After propensity score matching, no significant differences were observed between the age groups in OS (HR = 1.16; 95% CI: 0.76–1.77; p = 0.488), NRM (HR = 1.03; 95% CI: 0.64–1.67; p = 0.90) or PFS (HR = 1.20; 95% CI: 0.779–1.83; p = 0.40). PFS in patients ≥ 65 years was associated with high‐risk IPSS‐R stratification (p = 0.0056). The age group ≥ 65 years conferred higher risk of relapse compared to patients aged < 65 years (HR = 2.77; 95% CI: 1.07–7.15; p = 0.035). In patients ≥ 65 years, prevalence risk was associated to male sex, reduced‐intensity conditioning, mobilized blood cells, and prior treatment, while in those < 65 years, to complications and chronic GVHD (p < 0.05). HCT is feasible in elderly patients. However, age may influence disease progression in very high‐risk elderly patients and risk of relapse after transplantation.
- Open Access
- 20 February 2025
- Published by Universidade Federal do Estado do Rio de Janeiro UNIRIO in Revista de Pesquisa Cuidado é Fundamental Online
- Vol. 17
Construction and validation of an instrument for safe transfusion practice / Construção e validação de instrumento para a prática transfusional segura
Objetivo: construção de um instrumento, do tipo checklist, como subsídio para segurança transfusional beira-leito. Método: foi empregada a Técnica Delphi, contando com a participação de 18 especialistas em hemoterapia na primeira etapa e 11 na segunda. Para a validação de conteúdo, foi utilizado o cálculo do índice de validade de conteúdo, com concordância ≥ 80% na primeira e ≥ 90% na segunda rodada de julgamento. Resultados: na primeira fase, dos 67 itens iniciais, 15 foram retirados por contabilizar índice de validade de conteúdo < 80%. O instrumento foi reformulado para nova avaliação dos especialistas, contando com 53 itens e 11 observações e intervenções. Destes, 8 itens foram retirados por contabilizarem índice de validade de conteúdo < 90%. O coeficiente alfa de Cronbach calculado para o checklist foi de 0,8940. Conclusão: o checklist poderá auxiliar na segurança da assistência hemoterápica em enfermagem, visto que apresenta boa confiabilidade.
- 20 February 2025
- Published by Universidade Federal do Estado do Rio de Janeiro UNIRIO in Revista de Pesquisa Cuidado é Fundamental Online
- Vol. 17
Open AccessConstruction and validation of an instrument for safe transfusion practice / Construção e validação de instrumento para a prática transfusional segura
Objetivo: construção de um instrumento, do tipo checklist, como subsídio para segurança transfusional beira-leito. Método: foi empregada a Técnica Delphi, contando com a participação de 18 especialistas em hemoterapia na primeira etapa e 11 na segunda. Para a validação de conteúdo, foi utilizado o cálculo do índice de validade de conteúdo, com concordância ≥ 80% na primeira e ≥ 90% na segunda rodada de julgamento. Resultados: na primeira fase, dos 67 itens iniciais, 15 foram retirados por contabilizar índice de validade de conteúdo < 80%. O instrumento foi reformulado para nova avaliação dos especialistas, contando com 53 itens e 11 observações e intervenções. Destes, 8 itens foram retirados por contabilizarem índice de validade de conteúdo < 90%. O coeficiente alfa de Cronbach calculado para o checklist foi de 0,8940. Conclusão: o checklist poderá auxiliar na segurança da assistência hemoterápica em enfermagem, visto que apresenta boa confiabilidade.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1) , 270
Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators
Systematic evaluation of hematopoietic cell transplantation (HCT) outcomes is essential to improve clinical practice and meet international quality standards. In Brazil, the partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR) has advanced national data reporting and benchmarking through the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR). This study reports outcomes from 11,210 first HCTs (5,984 allogeneic; 5,226 autologous) performed between 2012 and 2023 across 44 Brazilian centers. Median recipient age was 29 years for allogeneic and 53 years for autologous transplants. Acute leukemias predominated among allogeneic cases, while multiple myeloma was the most common indication for autologous HCT. Two-year overall survival was 82.0% for autologous and 59.8% for allogeneic transplants, with variation by donor type (matched related 61.8%, mismatched related 54.0%, unrelated 63.3%). Two-year non-relapse mortality was 8.0% and 21.6% for autologous and allogeneic transplants, respectively. The cumulative incidence of grade II–IV acute graft-versus-host disease (GVHD) at two years was 29.9%, with chronic GVHD incidence of 29.5%. Two-year relapse incidence was 24.1% for allogeneic and 25.8% for autologous HCT. Despite challenges within the Brazilian healthcare system, these outcomes align with international registry data. Adequate data completeness supports the robustness of these findings. Our results highlight the quality of Brazilian transplant programs and underscore the value of standardized outcome monitoring to foster continuous improvement. Strengthening center participation, follow-up, and data management remains critical to maintaining registry quality and enhancing patient care.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1) , 270
Open AccessHematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators
Systematic evaluation of hematopoietic cell transplantation (HCT) outcomes is essential to improve clinical practice and meet international quality standards. In Brazil, the partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR) has advanced national data reporting and benchmarking through the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR). This study reports outcomes from 11,210 first HCTs (5,984 allogeneic; 5,226 autologous) performed between 2012 and 2023 across 44 Brazilian centers. Median recipient age was 29 years for allogeneic and 53 years for autologous transplants. Acute leukemias predominated among allogeneic cases, while multiple myeloma was the most common indication for autologous HCT. Two-year overall survival was 82.0% for autologous and 59.8% for allogeneic transplants, with variation by donor type (matched related 61.8%, mismatched related 54.0%, unrelated 63.3%). Two-year non-relapse mortality was 8.0% and 21.6% for autologous and allogeneic transplants, respectively. The cumulative incidence of grade II–IV acute graft-versus-host disease (GVHD) at two years was 29.9%, with chronic GVHD incidence of 29.5%. Two-year relapse incidence was 24.1% for allogeneic and 25.8% for autologous HCT. Despite challenges within the Brazilian healthcare system, these outcomes align with international registry data. Adequate data completeness supports the robustness of these findings. Our results highlight the quality of Brazilian transplant programs and underscore the value of standardized outcome monitoring to foster continuous improvement. Strengthening center participation, follow-up, and data management remains critical to maintaining registry quality and enhancing patient care.